Substrate in Medical Technology

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

... of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is ... in white blood cells and in the kidney, and reduced levels of the target substrate (GL-3), as measured in renal interstitial capillary cells from kidney ...

Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.

... Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an ...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

... supports a Phase 3 clinical trial comparing Amigal to placebo based on a surrogate primary endpoint of the change in the amount of kidney GL-3, the substrate that accumulates in the cells of Fabry patients. Amicus plans to continue discussions with the FDA through a Special Protocol Assessment (SPA) ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... if possible. Tasigna inhibits human P-glycoprotein. If Tasigna is administered with drugs that are substrates of Pgp, increased concentrations of the substrate are likely and caution should be exercised. Tasigna may also induce CYP2B6, CYP2C8, and CYP2C9. Therefore, Tasigna may alter serum concentration of ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... if possible. Tasigna inhibits human P-glycoprotein. If Tasigna is administered with drugs that are substrates of Pgp, increased concentrations of the substrate are likely and caution should be exercised. Tasigna may also induce CYP2B6, CYP2C8 and CYP2C9. Therefore, Tasigna may alter serum concentration of ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... cell cycle arrest, dose dependent apoptosis and a reduction in phospho-BAD levels in leukemia and lymphoma cell lines. Phospho-BAD is a direct substrate for PIM, and may serve as a useful in vivo biomarker for future clinical trials. Most notably, SGI-1776 induced significant tumor regression in ...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

... in phosphorylated CrkL in subjects dosed at 1.8 and 3.6 mg/kg, which reversed between 2 and 24 hours post-infusion. CrkL is a binding partner and substrate of BCR-ABL, and decreases in phosphorylation of CrkL are indicative of BCR-ABL kinase inhibition. XL228 also inhibits IGF1R and the insulin receptor, ...

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

... with horseradish peroxidase (HRP), and enzyme substrate plus chromogen. Absorbance is measured at 450 ... of HRP-conjugated goat anti-human IgG, and enzyme substrate plus chromogen. Absorbance is measured at 450 ... is added. After incubation and washing, the substrate is added. Absorbance is measured at 450 nm. ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

... renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved ... sitagliptin transport has not been established. Sitagliptin is also a substrate of p-glycoprotein, which may also be involved in mediating the renal ...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

... renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved ... sitagliptin transport has not been established. Sitagliptin is also a substrate of p-glycoprotein, which may also be involved in mediating the renal ...

Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease

... Nashville, TN. This presentation will include the first data from the Company demonstrating the reduction of globotriaosylceramide (GL-3), the lipid substrate that accumulates in Fabry disease, after oral administration of a pharmacological chaperone. These data were not available at the time of abstract ...

AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

... PI3K inhibiting small molecular compounds, we are positioning ourselves as one of the leaders in this promising therapeutic approach." Cellular substrate phosphorylation studies targeting the inhibition of PI3K and functional cellular assays of tumor cell proliferation have been performed. In addition, ...

terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

... small molecular compounds, we are positioning ourselves as one of the leaders in this promising therapeutic approach. Cellular substrate phosphorylation studies targeting the inhibition of PI3K and functional cellular assays of tumor cell proliferation have been performed. ...

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint

... Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a blood substitute, a liquid ventilation product and an implantable glucose sensor. These products are ...

New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk

... requires only two drops of solution placed on the palm of the hand. The first, digitonin, binds to skin cholesterol. The second contains an enzyme substrate that allows readout with a spectrophotometer. The test can be performed in minutes. PREVU(x) is marketed by McNeil Consumer Healthcare and ...

The Past, Present and Future of HLA Typing

... are now labeled with fluorescent dyes, biotin, digoxigenin, or directly with enzymes such as horseradish peroxidase. The appropriate substrate can be added to produce a fluorometric (or colorimetric) readout without the problems associated with radioactivity. Variations of the technique ...